- Adjusted diluted EPS grew 271% year-over-year to $0.12 in Q2 and 132% year-to-date to $0.86.
- Adjusted EBITDA margin improved by 330 basis points to 17%, with adjusted EBITDA increasing 19% year-over-year to $107 million.
- Adjusted gross profit margin increased 150 basis points to 45.7% driven by expense control and favorable product mix.
- Donor Screening revenue declined 61% due to business wind down; respiratory business revenue declined by $2 million excluding COVID.
- Molecular revenue grew 24% driven by support for Savanna customers during transition.
- Net debt increased by $81 million to $238 million; adjusted free cash flow was negative $32 million in Q2, in line with seasonal expectations.
- Non-GAAP operating expenses decreased by 9% due to cost savings in staffing and procurement.
- Q2 2025 total revenue was $614 million, a 1% growth excluding COVID and Donor Screening businesses.
Related items and other data are not available for this feed item.
Dafinchi